The fatal weakness of leukemia has been discovered

Scientists have discovered two kinds of signaling proteins that make cancer cells resistant to chemotherapy, and according to studies on recombinant human proteins, they can eliminate leukemia by blocking these signal proteins.

The findings are published in Nature Medicine, and researchers at the Cincinnati Children's Hospital Medical Center have shown that blocking the combination of signal protein c-Fos and Dusp1 may cure a variety of kinase-driven, refractory leukemia and solid Cancer, including acute myeloid leukemia (AML), lung cancer, breast cancer and chronic myeloid leukemia (CML).

"We believe that our data will change the way we think about cancer development and targeted care over the next five years," the researchers said. "This study identifies the potential weakness of the kinase to drive cancer, and we suggest that it is cured and not treated."

After identifying c-Fos and Dusp1, the researchers used a combination therapy approach. Treatment combinations include: 1. Personal therapy with tyrosine kinase inhibitors, imatinib; 2. Single inhibitor treatment of c-Fos Dusp1; 3. Imatinib treatment of two molecular inhibitors c-Fos Dusp1 binding treatment. The results of the study showed that after a month of treatment, 90% of the mice were treated with imatinib in combination with two molecular inhibitors, and there were no signs of residual disease. In addition, the researchers also found that the use of a single inhibitor can also eradicate the disease in mice.

Before the clinical trial, the researchers also need to repeatedly verify that they will continue to track the test c-Fos and Dusp1 on the kinase-driven effects of various types of cancer. Flarebio provides you with superior recombinant proteins like recombinant ECEL1 at competitive prices.

To study action mechanism of transport proteins ABCB1 and ABCG2

How is the resistance of cancer cells affected by ABC-transporter? A related new study paper through recombinant mouse proteins has been published in the open access journal BioDiscovery, studying the second generation tyrosine kinase inhibitor (TKI) - dasatinib (DAS) and ATP binding (ABC) transport proteins ABCB1 and ABCG2 mechanism to assess whether these drug transporters may impair the therapeutic effect.

The "targeted" treatment of cancer is an effective way to minimize the damage to healthy cells. Targeted therapy has revolutionized cancer treatment in the past few decades through the use of reasonably designed drugs that interfere with the specific molecules (molecular targets) necessary for the proliferation and survival of malignant cells.

Although DAS is an excellent choice for the treatment of chronic myeloid leukemia resistant to imatinib, recent laboratory studies have shown that the antiproliferative effect of DAS can be significantly reduced when ATP binds to ABC transporters, ABCB1 and ABCG2.

"Although this relationship is important, we still don't know whether these drug transporters will damage DAS's clinical treatment," explains Dr. Petr Mlejnek, Ph.D., Olomouc, University of Palacky, Czech Republic. "We believe that the expression level of drug transporters is a key factor in the outcome and may therefore help explain the existing controversy. We decided to study the relationship between ABCB1 and ABCG2 expression levels and in vitro resistance to DAS.

In their study, Dr. Petr Mlejnek from the University of Olomouc Palacky, Czech Republic, and his team observed that the expression level of ABC-transporters studied was an important factor influencing cell resistance. Although the anti-proliferative and pro-apoptotic effects of DAS can be reduced by ABCB1 or ABCG2 at clinically relevant concentrations, the actual effect of ABC transporters on DAS efficiency depends on their expression levels. The lower expression level of ABC transporters mediates lower resistance. Considering the fact that the expression levels of ABCB1 and ABCG2 transporters are almost not high in clinical samples, their contribution to overall resistance to DAS is significant. Flarebio offers high-quality recombinant proteins such as recombinant ECEL1 at good prices.

A new method used to treat asthma

A new study published in the Journal of Allergy and Clinical Immunology investigates a potential new approach for the treatment of asthma. According to research using recombinant human proteins, asthma causes the individual's airway to become inflamed and narrower and produce additional mucus. The patient's breathing becomes difficult, and the result is a wheezing and coughing. It is estimated that 12% of people in the United States suffer from asthma, equivalent to about 25 million people.

There is a series of potential triggers for asthma. These include pollen, mold, dust mite, animal dander, air pollution, certain medications and exercise. The current drugs can effectively treat many people's symptoms, but as the lead author of the study, Dr. Ruth Sander said, "For many people with asthma, especially severe asthma, treatment is not 100% effective. Although the study is aimed at new treatments for allergic-related asthma, it still requires new therapies for allergies that are independent of allergies, and the steady increase in asthma cases and their fatalities and the shortage of drugs in some individuals make asthma research an important area of research."

A recent study at the University of Leicester, UK, investigated the role of specific proteins in asthma, called the high mobility group box 1 (HMGB1). Researchers hope their findings may pave the way for more effective treatment. HMGB1 is a chromatin protein, meaning that it helps to tissue DNA and regulate its transcription in the nucleus. It is secreted by immune cells (including monocytes, macrophages and dendritic cells) and promotes inflammatory responses.

Current studies use mucus and muscle tissue from mild to moderate patients with asthma. It is known that the smooth muscle in the airway has a significant contribution to the symptoms of asthma; it is overly contracted and the quality is increased, and the chemicals involved in the inflammatory response are released. "As far as we know, this is the first study to show that HMGB1 has a direct effect on stimulating the increased airway muscle contraction, and this study has led us closer to improving the treatment of patients with severe asthma," Dr. Sanders continued.

This is the early stage of the study of this new approach. However, it marks an important leap; by understanding the role of HMGB1 and its role in asthma, eventually we can take new interventions. By the way, Flarebio provides you with high-quality recombinant proteins like recombinant ECEL1 at competitive prices.

Researchers from the Shanghai Institute of Health Sciences, Shanghai Jiaotong University School of Medicine recently used the human genome-wide transcription factor siRNA library to screen transcription factors which participate in the ESC self-renewal and found that a series of important genes which are important for maintaining human ESC, particularly the great importance and mechanism of PHB as a new member of HIRA complex in the regulation of human embryonic stem cells (embryonic stem cells, ESC) self-renewal. The study was published in the December 8 issue of Cell Stem Cell which also has other studies on recombinant human proteins, and the author of the article is Professor Jin Ying from Shanghai Jiaotong University School of Medicine.

In this study, the researchers used the human genome-wide transcription factor siRNA library to screen participants in the ESC self-renewal transcription factor and found a series of genes that play an important role in maintaining human ESC properties. They studied the PHB gene in particular. Previous studies have learned that PHB is involved in a variety of important life processes in mammalian cells. However, the function of the gene in the ESC has not been reported. The study of the Jinying group found that PHB plays an important role in maintaining human ESC self-renewal and promoting the reprogramming of human adult cells, especially PHB plays a unique role in maintaining the correct histone methylation of human ESC effect. Further studies have shown that PHBs interact with the HIRA complex of the chaperone protein H3.3 and maintain the protein stability of the HIRA complex.

In addition, the researchers found that PHB and HIRA jointly regulate the enrichment of H3.3 in the whole genome of chromatin, especially in the regulation of H3.3 in isocitrate dehydrogenases (IDHs) Gene promoter region and the expression of IDH gene to control the production of a-ketoglutarate (a-KG), a key metabolite that plays an important role in the fate of ESC, to shape the correct histones Methylation levels, maintenance of human hESC self-renewal and epigenetic characteristics.

This study reveals the key role of PHB in pluripotency regulation through genome-wide, large-scale siRNA screening, and it reported that PHB interacts with HIRA complex to regulate the enrichment of H3.3 on chromatin. This study also revealed the important regulation of HIRA complex and H3.3 on IDH gene expression and key metabolite a-KG, and proposed an apparent-metabolic regulatory loop maintained by human ESC. Flarebio provides you with good-quality recombinant proteins like recombinant ECEL1 at competitive prices.

New drugs for the treatment of multiple myeloma patients

Multiple myeloma is a cancer of bone marrow plasma cells. Plasma cells produce certain proteins that establish the immune system. According to research using recombinant dog proteins, when the number shows abnormalities, these proteins damage the body and the immune system.

"We are now able to diagnose and treat myeloma earlier before it begins to damage the body, thus effectively controlling myeloma, and any irreversible damage to the body may be significantly delayed," said Dr. Sikander Ailawadhi, haematologist and oncologist from Jacksonville Mayo Clinic Cancer Center.

In 2015, the US Food and Drug Administration approved three new drugs for the treatment of multiple myeloma in two weeks. "The approval of these drugs for the treatment of diseases that are considered to be incurable in such a short period of time is unprecedented," Ailawadhi said. "Most patients showed symptom relief, and their survival rate has been improved."

"We can almost guarantee that every patient who has been diagnosed with newly diagnosed myeloma has a certain degree of reaction," he added.

"Some of the most exciting things are the development of new drugs," Ailawadhi explained. "Specifically, we can use the currently available drugs to observe what resistance to drive myeloma cells and to isolate those pathways and then to develop new drugs that specifically target those resistance mechanisms."

Ailawadhi says that more drugs are coming soon. At present, the Mayo Clinic has more than 50 active clinical trials. Flarebio offers recombinant proteins of good quality such as recombinant ECEL1.

New way of identifying subtypes of Alzheimer's disease

Recently, scientists have published an article on early identification of the onset of progressive Alzheimer's disease in the journal Nature which also publishes some other studies on recombinant dog proteins, providing some basis for individual and precise treatment of Alzheimer's disease.

Researchers at the National Institutes of Health and the College of Neurology of the London College of Medicine have found that the type of fibrogenesis is associated with subtypes of Alzheimer's disease. A study published by them on nature described: the formation of brain tissue deposition of amyloid fibrils can reflect the physiological characteristics of Alzheimer's disease. The study found that the type of fiber with the degree of disease and pathological subtypes would show different morphological or size differences. According to this, we can classify the types of early Alzheimer's disease. This is a time-consuming and labor-intensive experimental project, so the relevant research is rare. To investigate the problem, the authors collected 37 tissue samples from the brain tissue of 18 dementia sufferers of the late Alzheimer's disease. They used magnetic resonance techniques to detect the deposition of these brain β-amyloid forms, while the clinical classification of these patients was compared. (Some patients were diagnosed with rapid progression; some patients were diagnosed as classic; and some patients had posterior cortical atrophy). The researchers found that classic patients with cerebral cortical atrophy have the same pattern with patients with cerebral β-amyloid deposition. However, the pattern of amyloid deposition in patients with rapid progression is often different from that of other types of patients.

The researchers believe that the rapid progress of Alzheimer's disease has a special β-like protein deposition pattern, resulting in the condition that the type of brain tissue in patients with fibrous lesions of the size and morphology are different from other types. This helps early identification of rapidly progressing Alzheimer's disease patients and gives them timely treatment. Researchers have also admitted that because the number of specimens is too small, the mechanism is not clear. Further studies remain to be carried out, and greater progress will be made. Flarebio provides you with superior recombinant proteins like recombinant ECEL1 at good prices.

A research team has found a new approach to shut down CRISPR-Cas9

A recent research team has found a new approach to shut down CRISPR-Cas9 that addresses potential problems with CRISPR-Cas9 gene editing methods. The team used phage proteins, allowing more precise gene editing and giving the researchers the ability to disable the entire system. Details have been published in the December 29 issue of the Journal of Cell, which also publishes some other studies on recombinant dog proteins. Prior to this, in another study published by Cell, scientists discovered the first known "off switch" for CRISPR - Cas9 activity.

CRISPR-Cas9 is a method used by scientists to edit the genome. Cas9 is an enzyme that cleaves DNA fragments so that they can be replaced. The CRISPR-Cas9 system is naturally occurring in bacteria and is a method for combating phage and targeting bacteria only. It is able to cut and store viral DNA slices to allow bacteria to recognize phages in the future. Researchers use this system to modify the genome and repair genetic diseases. However, CRISPR-Cas9 occasionally goes wrong. In the past, scientists had no way to disable the system, leading to security issues of future human trials.

Researchers from the University of California, San Francisco have explored possible ways to inactivate the CRISPR-Cas9 system. CRISPR-Cas9 is mainly a method of fighting bacteria and viruses, but the team observed the infected bacteria. If the bacterium infects the bacterium and inserts its DNA, Cas9 tries to cut it off even if it will target the bacteria's own genome. Because the virus needs to have a live host, this will not help the virus. The team hypothesized that some phages had an anti-CRISPR protein for inactivation of Cas9. In screening the bacteria infected in this way, the team found two anti-CRISPR proteins, known as AcrIIA2 and AcrIIA4. Both proteins were able to inhibit the Cas9 enzyme. AcrIIA2 and AcrIIA4 can be used to inactivate Cas9, shutting down the entire CRISPR-Cas9 system.

The team's findings will allow scientists to better control gene editing. If the CRISPR-Cas9 system starts making mistakes, the researcher can disable it. The system can be temporarily or permanently shut down, which make the technology will more secure for final human trials. Flarebio provides good-quality recombinant proteins such as recombinant ECEL1 at competitive prices.

Scientists solve some puzzles of necrocytosis

Normally our tissues are healthy, but some of them will develop inflammation and disease. "What is it that causes inflammation? Is necroptosis the switch to inflammation? How does this process work?" said Manolis Pasparakis, professor of genetics at the University of Cologne, Germany. Professor Pasparakis' group of researchers published an article in the November 7 issue of Nature which also publishes other studies on recombinant horse proteins, partly answering these questions.

Professor Pasparakis' team constructed special skin cells: mice had RIPK1 lack in keratinocytes. The researchers had originally thought that the cells did not develop procedural necrosis due to RIPK1 deficiency, but the researchers got the opposite result: the cells keratinocytes in mice showed necrosis and died, triggering skin inflammation. By further analysis, the researchers found the answer. Because RIPK1 will inhibit another procedural necrosis factor: ZBP1 protein, genetic removal of ZBP1 can inhibit the RIPK1 deletion caused by necrocytosis and inflammation.

"We know that ZBP1 is a DNA-sensing protein that is involved in fighting the immune system of certain viruses but has yet to find its role in inflammation," said Chun Kim, co-author of the paper. So how does RIPK1 suppress ZBP1?

To answer this question, the researchers used the CRISPR gene editor to modify three amino acids in the RHIM domain, a key structure for the interaction of RIPK1 with two other proteins that regulate necrocytosis. Mice that express this mutated RIPK1 in all cells will not survive after birth. But only in the expression of keratinocytes will just lead to skin inflammation.

The researchers found that when RIPK1 PHIM domain shows mutations, ZBP1 will open necrocytosis, leading to perinatal mortality and adult skin inflammation. "This surprising result is that the three amino acids of RIPK1 can prevent ZBP1-induced necrosis, and it is the key to survival of mice and prevention of skin inflammation," said Juan Lin, one of the authors.

"We solved some of the puzzles, but there are bigger puzzles still unclear," Pasparakis said. "ZBP1 acts as a viral sensor, and now our study associates it with inflammation and death." In most cases, chronic inflammation in the human body is still a mystery. Why do some cases of inflammation in the human body happen? Our study found the important role of ZBP1. Now we wonder whether the virus or bacteria can activate ZBP1. The next step researchers will explore the further association of ZBP1 and inflammation in the human body. Flarebio provides you with good-quality recombinant proteins including recombinant ECEL1.